

SUPPLEMENTARY MATERIAL

Table 1. Clinical Vignettes

A 20 year old woman with SLE is starting HCQ. She is 62 inches and 45 kg. What dosage would you most likely recommend?	
200 mg/day	42 (65.6%)*
400 mg every other day	1 (1.6%)
Alternating 200 mg/day and 400 mg/day	10 (15.6%)
400 mg/day	5 (7.8%)
Other	6 (9.4%)
A 45-year-old Asian woman with SLE is starting HCQ. She is 63 inches and 77 kg (BMI 30.1). What dosage would you be most likely to recommend?	
200 mg/day	6 (9.4%)
400 mg every other day	3 (4.7%)
Alternating 200 mg/day and 400 mg/day	9 (14.0%)
400 mg/day	42 (65.6%)*
Other	4 (6.3%)
A 45 year old Asian woman with SLE has active discoid rash and has been on HCQ for 5 years. She is 75 kg. What is the maximum dose of HCQ you are willing to recommend?	
200 mg/day	4 (6.3%)
400 mg/day	50 (78.1%)*
600 mg/day	6 (9.3%)
Other	4 (6.3%)
A 55 year old woman with SLE has been well controlled on 400 mg HCQ/day for 25 years. She is 65 kg. In considering potential benefit vs. risk of side effects, what would you be most likely to recommend?	
200 mg/day	23 (35.9%)
400 mg every other day	0 (0%)
Alternating 200 mg/day and 400 mg/day	30 (46.8%) *
400 mg/day	3 (4.7%)
Discontinue HCQ	4 (6.3%)
Other	4 (6.3%)

*= Per AAO guidelines

Table 2. Evaluation of risk factors associated with retinal toxicity*

Age	
0	11 (17.2%)
1	17 (26.6%)
2	8 (12.5%)
3	17 (26.6%)
4	11 (17.2%)
Race	
0	35 (54.7%)
1	14 (21.8%)
2	12 (18.8%)
3	2 (3.1%)
4	1 (1.6%)
High BMI: overweight/obese	
0	27 (42.2%)
1	18 (28.1%)
2	10 (15.6%)
3	6 (9.4%)
4	3 (4.7%)
Low BMI: underweight	
0	14 (21.9%)
1	15 (23.4%)
2	19 (29.7%)
3	13 (20.3%)
4	3 (4.7%)
Familial predisposition	
0	30 (46.9%)
1	11 (17.2%)
2	12 (18.7%)
3	9 (14.1%)
4	2 (3.1%)
Pre-existing retinal/macular disease	
0	6 (9.4%)
1	13 (20.3%)
2	10 (15.6%)
3	16 (25.0%)
4	19 (29.7%)

Liver disease	
0	12 (18.7%)
1	11 (17.2%)
2	24 (37.5%)
3	11 (17.2%)
4	6 (9.4%)
Renal disease	
0	2 (3.1%)
1	7 (10.9%)
2	17 (26.6%)
3	20 (31.3%)
4	18 (28.1%)
Concomitant tamoxifen use	
0	7 (10.9%)
1	9 (14.1%)
2	13 (20.3%)
3	15 (23.4%)
4	20 (31.3%)
Excessive daily dose of CQ/HCQ	
0	2 (3.1%)
1	3 (4.7%)
2	6 (9.4%)
3	15 (23.4%)
4	38 (59.4%)
Cumulative dose of CQ/HCQ	
0	0 (0%)
1	4 (6.3%)
2	4 (6.3%)
3	16 (25.0%)
4	40 (62.5%)

*0: no risk, 4: strong risk/presumed causation